Prior to surgery, mice were randomized to one of two treatment groups or a control group (n = 10 per group). Mice in the vancomycin group were subcutaneously administered a therapeutic dose of vancomycin (110 mg/kg twice daily) (Mylan, Cannonsburg, PA), which approximated the area under the curve (AUC) of 440 μg⋅h/ml for typical human exposure for vancomycin (1g twice daily).[29 (link)–31 (link)] Mice in the combination therapy group were administered a therapeutic subcutaneous mouse dose of rifampin (25 mg/kg daily) (Fresenius Kabi, Lake Zurich, IL) in addition to vancomycin therapy (110 mg/kg twice daily).[32 (link)] This rifampin dose was chosen based on previously published studies of various mouse models of staphylococcal infection.[32 (link)–36 (link)] All antibiotic therapy and sham injections of sterile saline were initiated on postoperative day 7 and continued through postoperative day 14 to mimic the treatment of an established SII. The MICs for Xen36 were ≤0.5 μg/ml for vancomycin and ≤0.5 μg/ml for rifampin.
Hu Y., Hegde V., Johansen D., Loftin A.H., Dworsky E., Zoller S.D., Park H.Y., Hamad C.D., Nelson G.E., Francis K.P., Scaduto A, & Bernthal N.M. (2017). Combinatory antibiotic therapy increases rate of bacterial kill but not final outcome in a novel mouse model of Staphylococcus aureus spinal implant infection. PLoS ONE, 12(2), e0173019.
+ Open protocol